SELLAS Life Sciences Group, Inc.
7 Times Square, Suite 2503
New York, New York 10036
April 27, 2021
Via EDGAR
Margaret Schwartz
United States Securities and Exchange Commission
Division of Corporate Finance
100 F Street, N.E.
Washington, D.C. 20549
| Re: | SELLAS Life Sciences Group, Inc. |
Registration Statement on Form S-3
File No. 333-255318
Acceleration Request
Dear Ms. Schwartz,
Pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, SELLAS Life Sciences Group, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-255318), so that it may become effective at 5:00 p.m. (Washington, D.C. time) on Thursday, April 29, 2021, or as soon thereafter as practicable.
Please call Daniel A. Bagliebter, of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, at (212) 692-6856 with any comments or questions regarding the Registration Statement.
| Very truly yours, | |
| SELLAS Life Sciences Group, Inc. | |
| /s/ Angelos M. Stergiou | |
| By: Angelos M. Stergiou, M.D., Sc.D., h.c. | |
| Its: President and Chief Executive Officer |
| cc: | Barbara A. Wood, SELLAS Life Sciences Group, Inc. |
Daniel A. Bagliebter, Esq., Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.